◎ Sugi Atlas

Atlas / Drug / Povorcitinib

Povorcitinib

drug
On this page

Also known as INCB-054707Incb054707

Summary

Povorcitinib (CHEMBL5095079) is a phase-3 clinical-stage small molecule targeting JAK1; indicated across 4 conditions including vitiligo and hidradenitis suppurativa.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (JAK1)
  • Indications: 4 conditions
  • Clinical trials: 24
  • Chemistry: 507.5 Da · C23H22F5N7O

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL5095079
NamePovorcitinib
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID86280672
Molecular formulaC23H22F5N7O
Molecular weight507.5
InChIKeyMSGYSFWCPOBHEV-AWEZNQCLSA-N

SMILES: CC1=C(C(=NN1)C)C2=CN(N=C2)C3(CN(C3)C4=C(C=C(C(=C4)F)C(=O)N[C@@H](C)C(F)(F)F)F)CC#N

IUPAC name: 4-[3-(cyanomethyl)-3-[4-(3,5-dimethyl-1H-pyrazol-4-yl)pyrazol-1-yl]azetidin-1-yl]-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide

Also known as: INCB-054707, Incb054707, INCB054707, Povorcitinib, POVORCITINIB

Parent form; salt/anhydrous children: CHEMBL5314592

Patent coverage: 61 distinct patent families (224 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
JAK1Janus kinase 1Inhibition6.522.8%P23458

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Tyrosine-protein kinase JAK1, Tyrosine-protein kinase JAK2, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, Tyrosine-protein kinase receptor UFO, Tyrosine-protein kinase receptor TYRO3, Tyrosine-protein kinase Mer.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 17 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
JAK17.12IC5075nMCHEMBL_ACT_28013678
PIK3CD6.6IC50250nMCHEMBL_ACT_26930143
PIK3CD6.6IC50250nMCHEMBL_ACT_26930149
TYRO36.52IC50300nMCHEMBL_ACT_26791223
AXL6.52IC50300nMCHEMBL_ACT_26791229
TYRO36.52IC50300nMCHEMBL_ACT_26791232
JAK26.19IC50650nMCHEMBL_ACT_27555461
JAK26.19IC50650nMCHEMBL_ACT_27555503
JAK26.19IC50650nMCHEMBL_ACT_27749969
JAK26.19IC50650nMCHEMBL_ACT_27750011
JAK26.19IC50650nMCHEMBL_ACT_28957091
MERTK5.7IC502000nMCHEMBL_ACT_26781194
AXL5.7IC502000nMCHEMBL_ACT_26781197
MERTK5.7IC502000nMCHEMBL_ACT_27837155
AXL5.7IC502000nMCHEMBL_ACT_27837158
MERTK5.7IC502000nMCHEMBL_ACT_28527671
AXL5.7IC502000nMCHEMBL_ACT_28527674

Target pathways

Aggregated over 1 target gene(s): JAK1.

Top Reactome pathways

52 total, by targets touching each:

PathwayTargetsGenes
Interleukin-6 signaling1JAK1
MAPK3 (ERK1) activation1JAK1
RAF-independent MAPK1/3 activation1JAK1
MAPK1 (ERK2) activation1JAK1
ISG15 antiviral mechanism1JAK1
Antimicrobial mechanism of IFN-stimulated genes1JAK1
Interleukin-7 signaling1JAK1
Cytokine Signaling in Immune system1JAK1
Signal Transduction1JAK1
Disease1JAK1
Immune System1JAK1
Interleukin-12 family signaling1JAK1
Signaling by Interleukins1JAK1
Other interleukin signaling1JAK1
Interleukin-2 family signaling1JAK1
Interleukin-3, Interleukin-5 and GM-CSF signaling1JAK1
Infectious disease1JAK1
RAF/MAP kinase cascade1JAK1
MAPK family signaling cascades1JAK1
MAPK1/MAPK3 signaling1JAK1
Interleukin-6 family signaling1JAK1
Interleukin-10 signaling1JAK1
Interleukin-4 and Interleukin-13 signaling1JAK1
IL-6-type cytokine receptor ligand interactions1JAK1
Interferon gamma signaling1JAK1
Regulation of IFNG signaling1JAK1
Interleukin-20 family signaling1JAK1
Interleukin-15 signaling1JAK1
Interleukin-35 Signalling1JAK1
Interleukin-9 signaling1JAK1
Interleukin-2 signaling1JAK1
Interleukin-12 signaling1JAK1
Interleukin-27 signaling1JAK1
Interleukin-21 signaling1JAK1
Interferon alpha/beta signaling1JAK1
Interleukin receptor SHC signaling1JAK1
Regulation of IFNA/IFNB signaling1JAK1
Interferon Signaling1JAK1
Signaling by CSF3 (G-CSF)1JAK1
Potential therapeutics for SARS1JAK1
SARS-CoV Infections1JAK1
SARS-CoV-2 Infection1JAK1
Inactivation of CSF3 (G-CSF) signaling1JAK1
SARS-CoV-2 activates/modulates innate and adaptive immune responses1JAK1
SARS-CoV-2-host interactions1JAK1
IFNG signaling activates MAPKs1JAK1
Respiratory Syncytial Virus Infection Pathway1JAK1
Viral Infection Pathways1JAK1
Evasion by RSV of host interferon responses1JAK1
RSV-host interactions1JAK1

Dominant GO biological processes

GO termTargets
protein phosphorylation1
cell surface receptor signaling pathway via JAK-STAT1
cytokine-mediated signaling pathway1
cell differentiation1
positive regulation of homotypic cell-cell adhesion1
intracellular signal transduction1
interleukin-15-mediated signaling pathway1
interleukin-4-mediated signaling pathway1
interleukin-2-mediated signaling pathway1
interleukin-7-mediated signaling pathway1
interleukin-9-mediated signaling pathway1
interleukin-11-mediated signaling pathway1
type III interferon-mediated signaling pathway1
response to antibiotic1
type II interferon-mediated signaling pathway1

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
vitiligo3MONDO:0008661EFO:0004208
hidradenitis suppurativa3MONDO:0006559EFO:1000710
asthma2MONDO:0004979MONDO:0004979
prurigo1MONDO:0021739MONDO:0021739

Clinical trials

Total trials: 24.

Phase distribution

PhaseTrials
PHASE38
PHASE28
PHASE18

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06113445PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113471PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06212999PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06516952PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516965PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06855498PHASE3RECRUITINGRollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT05620823PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT05620836PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05851443PHASE2RECRUITINGA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT07213973PHASE2RECRUITINGPharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT03569371PHASE2COMPLETEDA Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT03607487PHASE2COMPLETEDA Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT04476043PHASE2COMPLETEDTo Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT04818346PHASE2COMPLETEDA Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
NCT05061693PHASE2COMPLETEDA Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
NCT05936567PHASE2COMPLETEDStudy Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT07588139PHASE1RECRUITINGA Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
NCT05068466PHASE1COMPLETEDA Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
NCT05624710PHASE1COMPLETEDA Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05624723PHASE1COMPLETEDStudy to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
NCT06380205PHASE1COMPLETEDA Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
NCT06416800PHASE1COMPLETEDA Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
NCT06441318PHASE1COMPLETEDA Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
NCT06505265PHASE1COMPLETEDA Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

67 molecules share ≥1 primary target. Top 67 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)JAK1
DEUCRAVACITINIBChEMBL + PubChemPhase 4 (approved)JAK1
RITLECITINIBChEMBL + PubChemPhase 4 (approved)JAK1
ABROCITINIBChEMBLPhase 4 (approved)JAK1
BARICITINIBChEMBLPhase 4 (approved)JAK1
CERITINIBChEMBLPhase 4 (approved)JAK1
ENTRECTINIBChEMBLPhase 4 (approved)JAK1
FEDRATINIBChEMBLPhase 4 (approved)JAK1
FILGOTINIBChEMBLPhase 4 (approved)JAK1
MIDOSTAURINChEMBLPhase 4 (approved)JAK1
MOMELOTINIBChEMBLPhase 4 (approved)JAK1
NINTEDANIBChEMBLPhase 4 (approved)JAK1
PACRITINIBChEMBLPhase 4 (approved)JAK1
PEFICITINIBChEMBLPhase 4 (approved)JAK1
PONATINIBChEMBLPhase 4 (approved)JAK1
RUXOLITINIBChEMBLPhase 4 (approved)JAK1
SUNITINIBChEMBLPhase 4 (approved)JAK1
TOFACITINIBChEMBLPhase 4 (approved)JAK1
UPADACITINIBChEMBLPhase 4 (approved)JAK1
ABIVERTINIBChEMBLPhase 3JAK1
BREPOCITINIBChEMBLPhase 3JAK1
DELGOCITINIBChEMBLPhase 3JAK1
DOVITINIBChEMBLPhase 3JAK1
ITACITINIBChEMBLPhase 3JAK1
IVARMACITINIBChEMBLPhase 3JAK1
LESTAURTINIBChEMBLPhase 3JAK1
MOTESANIBChEMBLPhase 3JAK1
ZASOCITINIBChEMBLPhase 3JAK1
APITOLISIBChEMBLPhase 2JAK1
AT-9283ChEMBLPhase 2JAK1
ATINVICITINIBChEMBLPhase 2JAK1
AZD-1480ChEMBLPhase 2JAK1
BMS-911543ChEMBLPhase 2JAK1
CC-401ChEMBLPhase 2JAK1
CERDULATINIBChEMBLPhase 2JAK1
DECERNOTINIBChEMBLPhase 2JAK1
GANDOTINIBChEMBLPhase 2JAK1
GOLIDOCITINIBChEMBLPhase 2JAK1
GUSACITINIBChEMBLPhase 2JAK1
IFIDANCITINIBChEMBLPhase 2JAK1
IZENCITINIBChEMBLPhase 2JAK1
LEPZACITINIBChEMBLPhase 2JAK1
LONDAMOCITINIBChEMBLPhase 2JAK1
NEZULCITINIBChEMBLPhase 2JAK1
NS-018ChEMBLPhase 2JAK1
OCLACITINIBChEMBLPhase 2JAK1
PICTILISIBChEMBLPhase 2JAK1
R-406ChEMBLPhase 2JAK1
REBASTINIBChEMBLPhase 2JAK1
ROPSACITINIBChEMBLPhase 2JAK1
SOLCITINIBChEMBLPhase 2JAK1
SOTRASTAURINChEMBLPhase 2JAK1
SU-014813ChEMBLPhase 2JAK1
TG100-115ChEMBLPhase 2JAK1
TOZASERTIBChEMBLPhase 2JAK1
ZOTIRACICLIBChEMBLPhase 2JAK1
AfatinibPubChemApprovedJAK1
BinimetinibPubChemApprovedJAK1
dacomitinibPubChemApprovedJAK1
FostamatinibPubChemApprovedJAK1
GefitinibPubChemApprovedJAK1
IdelalisibPubChemApprovedJAK1
ImatinibPubChemApprovedJAK1
PazopanibPubChemApprovedJAK1
regorafenibPubChemApprovedJAK1
SelumetinibPubChemApprovedJAK1
TrametinibPubChemApprovedJAK1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot